Meteor Biotech opens site at UCLA to support biotech research
Ella Day | June 11, 2025 | News story | Biotech/start-up, Research and Development, Sales and Marketing | Devices, Immunology, Meteor Biotech, Oncology, Pharmacy, University of California Los Angeles, cell sorting technology, clinical trials, research facility
South Korean spatial omics specialist, Meteor Biotech, has announced the opening of its first international office at the California NanoSystems Institute, University of California, Los Angeles (UCLA). The new site aims to support researchers using Meteor’s spatially-resolved laser-activated cell sorting (SLACS) technology and facilitate the development of new therapies across oncology, immunology and neuroscience.
The UCLA facility will serve as a demonstration and support hub, offering trials, pilot studies, and researcher training in spatial biology and single-cell analysis. No manufacturing is currently planned at the site.
SLACS, Meteor’s proprietary cell-sorting platform, enables the precise identification and retrieval of cells from tissue sections, overcoming limitations in existing spatial analysis tools. The company’s CosmoSort device, powered by SLACS, is designed to help researchers analyse complex tissue microenvironments with high spatial resolution, accelerating biomarker discovery and drug development.
“Establishing our first US office at UCLA, home to world-class research and biotech, marks a strategic leap forward for Meteor,” said Amos Lee, co-founder and CEO. “We are gearing up to accelerate wider global adoption of our spatial cell sorting technology, with Europe identified as the next strategic area.”
The move capitalises on the US’ position in biomedical research, with $48bn in National Institute of Health funding allocated in 2025. Meteor plans to scale its local presence in line with customer demand, including future hires in applications and sales support.
Ella Day
11/6/25
Related Content
Vesper Bio reports positive topline results for dementia candidate
Vesper Bio, a clinical-stage biotech developing novel oral therapies for neurodegenerative and neuropsychiatric disorders, has …
Von Willebrand disease – increasing awareness and access to vital care
Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about …
Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …
